Randomized pilot trial of eight weeks of Bedaquiline (TMC207) treatment for multidrug-resistant Tuberculosis: Long-term outcome, tolerability, and effect on emergence of drug resistance
<p>The 2-year follow-up results for a randomized placebo-controlled study of 47 patients with multidrug-resistant pulmonary tuberculosis treated with either the new diarylquinoline TMC207, recently renamed